101 related articles for article (PubMed ID: 18237249)
1. Neoadjuvant therapy with celecoxib to women with early stage breast cancer.
Tfayli A; Yang J; Kojouri K; Kesserwan C; Jafari M; Ozer H
Neoplasma; 2008; 55(2):122-6. PubMed ID: 18237249
[TBL] [Abstract][Full Text] [Related]
2. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study.
Ferrandina G; Ranelletti FO; Legge F; Lauriola L; Salutari V; Gessi M; Testa AC; Werner U; Navarra P; Tringali G; Battaglia A; Scambia G
Clin Cancer Res; 2003 Oct; 9(12):4324-31. PubMed ID: 14555502
[TBL] [Abstract][Full Text] [Related]
3. Celecoxib decreases Ki-67 proliferative index in active smokers.
Mao JT; Fishbein MC; Adams B; Roth MD; Goodglick L; Hong L; Burdick M; Strieter ER; Holmes C; Tashkin DP; Dubinett SM
Clin Cancer Res; 2006 Jan; 12(1):314-20. PubMed ID: 16397057
[TBL] [Abstract][Full Text] [Related]
4. Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells.
Suh YJ; Chada S; McKenzie T; Liu Y; Swisher SG; Lucci A; Hunt KK
Surgery; 2005 Sep; 138(3):422-30. PubMed ID: 16213894
[TBL] [Abstract][Full Text] [Related]
5. Increases in circulating VEGF levels during COX-2 inhibitor treatment in breast cancer patients.
Ueno T; Chow LW; Toi M
Biomed Pharmacother; 2006 Jul; 60(6):277-9. PubMed ID: 16806797
[TBL] [Abstract][Full Text] [Related]
6. Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation.
Haffty BG; Yang Q; Moran MS; Tan AR; Reiss M
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1006-13. PubMed ID: 18262731
[TBL] [Abstract][Full Text] [Related]
7. The anti-proliferative potency of celecoxib is not a class effect of coxibs.
Schiffmann S; Maier TJ; Wobst I; Janssen A; Corban-Wilhelm H; Angioni C; Geisslinger G; Grösch S
Biochem Pharmacol; 2008 Jul; 76(2):179-87. PubMed ID: 18547544
[TBL] [Abstract][Full Text] [Related]
8. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
9. Pilot randomized phase II study of celecoxib in oral premalignant lesions.
Papadimitrakopoulou VA; William WN; Dannenberg AJ; Lippman SM; Lee JJ; Ondrey FG; Peterson DE; Feng L; Atwell A; El-Naggar AK; Nathan CO; Helman JI; Du B; Yueh B; Boyle JO
Clin Cancer Res; 2008 Apr; 14(7):2095-101. PubMed ID: 18381950
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.
Lustberg MB; Povoski SP; Zhao W; Ziegler RM; Sugimoto Y; Ruppert AS; Lehman AM; Shiels DR; Mrozek E; Ramaswamy B; Layman RM; Brueggemeier RW; Shapiro CL
Clin Breast Cancer; 2011 Aug; 11(4):221-7. PubMed ID: 21729671
[TBL] [Abstract][Full Text] [Related]
11. Effects of a selective cyclooxygenase-2 inhibitor on endometrial epithelial cells from patients with endometriosis.
Olivares C; Bilotas M; Buquet R; Borghi M; Sueldo C; Tesone M; Meresman G
Hum Reprod; 2008 Dec; 23(12):2701-8. PubMed ID: 18716040
[TBL] [Abstract][Full Text] [Related]
12. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
13. uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer.
Qin W; Zhu W; Hewett JE; Rottinghaus G; Chen YC; Flynn JT; Kliethermes B; Mannello F; Sauter ER
BMC Cancer; 2008 Oct; 8():298. PubMed ID: 18922176
[TBL] [Abstract][Full Text] [Related]
14. COX-2 overexpression in pretreatment biopsies predicts response of rectal cancers to neoadjuvant radiochemotherapy.
Smith FM; Reynolds JV; Kay EW; Crotty P; Murphy JO; Hollywood D; Gaffney EF; Stephens RB; Kennedy MJ
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):466-72. PubMed ID: 16213106
[TBL] [Abstract][Full Text] [Related]
15. The effects of cyclooxygenase-2 expression in prostate cancer cells: modulation of response to cytotoxic agents.
Mehar A; Macanas-Pirard P; Mizokami A; Takahashi Y; Kass GE; Coley HM
J Pharmacol Exp Ther; 2008 Mar; 324(3):1181-7. PubMed ID: 18089846
[TBL] [Abstract][Full Text] [Related]
16. Breast infiltrating ductal carcinoma: analysis of hormone, HER-2 receptors and Ki-67 proliferation marker.
Mustać E; Zamolo G; Petković M; Dordević G; Radić J; Grgurević E; Batinac T
Coll Antropol; 2008 Sep; 32(3):741-6. PubMed ID: 18982746
[TBL] [Abstract][Full Text] [Related]
17. Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial.
Kubista E; Planellas Gomez JV; Dowsett M; Foidart JM; Pohlodek K; Serreyn R; Nechushkin M; Manikhas AG; Semiglazov VF; Hageluken CC; Singer CF
Clin Cancer Res; 2007 Jul; 13(14):4185-90. PubMed ID: 17634547
[TBL] [Abstract][Full Text] [Related]
18. Molecular responses of rectal cancer to preoperative chemoradiation.
Debucquoy A; Goethals L; Geboes K; Roels S; Mc Bride WH; Haustermans K
Radiother Oncol; 2006 Aug; 80(2):172-7. PubMed ID: 16905208
[TBL] [Abstract][Full Text] [Related]
19. A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment.
Herrera FG; Chan P; Doll C; Milosevic M; Oza A; Syed A; Pintilie M; Levin W; Manchul L; Fyles A
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):97-103. PubMed ID: 17056201
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
Mutter R; Lu B; Carbone DP; Csiki I; Moretti L; Johnson DH; Morrow JD; Sandler AB; Shyr Y; Ye F; Choy H
Clin Cancer Res; 2009 Mar; 15(6):2158-65. PubMed ID: 19276291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
